Growth-Promoting and Psychological Effects of High-Dose Growth Hormone Treatment in Children with Intrauterine Growth Retardation.

DOI Web Site 被引用文献6件 参考文献28件
  • Tanaka Toshiaki
    Department of Endocrinology & Metabolism, National Children’s Medical Research Center, Tokyo, Japan
  • Matsuo Nobutake
    Department of Pediatrics, Keio University, Tokyo, Japan
  • Seino Yoshiki
    Department of Pediatrics, Okayama University, Okayama, Japan
  • Fujieda Kenji
    Department of Pediatrics, Hokkaido University, Sapporo, Japan
  • Yokoya Susumu
    Department of Pediatrics, Toranomon Hospital, Tokyo, Japan
  • Tachibana Katsuhiko
    Division of Endocrinology & Metabolism, Kanagawa Children’s Medical Center, Yokohama, Japan

この論文をさがす

抄録

The effect of growth hormone (GH) treatment was evaluated in non-growth hormone deficient (GHD) short children with intrauterine growth retardation (IUGR). The 104 short children with IUGR enrolled in the study were divided into three groups. Group A received recombinant human growth hormone (rhGH, Genotropin) 0.5 IU/kg/week 6 or 7 times a week in the first year and 1.0 IU/kg/week in the second year. Group B received rhGH 1.0 IU/kg/week for two years and Group C received rhGH 2.0 IU/kg/week for two years. Mean growth velocity increased from 5.6 cm/year before treatment to 7.2 cm/year in the first year and to 7.4 cm/year in the second year in Group A, from 5.3 cm/year to 8.4 cm/year in the first year and to 7.1 cm/year in the second year in Group B, and from 5.3 cm/year to 10.0 cm/year in the first year and to 7.2 cm/year in the second year in Group C. Mean serum IGF-I was 194.5 ng/ml, 281.7 ng/ml, and 339.0 ng/ml after 12 months of treatment, and 246.9 ng/ml, 305.0 ng/ml, and 318.9 ng/ml after 24 months of treatment in Groups A, B, and C, respectively. Bone age advanced 1.52 years, 1.39 years, and 1.48 years in the first year, and 1.18 years, 1.20 years, and 1.30 years in the second year, respectively. Mean increments in height standard deviation score (SDS) during the two years were 0.89 standard deviation in Group A, 1.09 SD in Group B, and 1.40 SD in Group C. Although a diabetic blood curve on oral glucose tolerance test (oGTT) was observed in a few children, neither increased HbA1c level nor clinical diabetic symptoms were observed. There were no other serious adverse events during GH treatment. This study showed clearly that GH treatment improved such psychosocial problems caused by the patients’ short stature such as self-consciousness about their height, mocking and bullying. High-dose GH administration for 2 years significantly improves height velocity, height SDS, and quality of life in IUGR short children.

収録刊行物

被引用文献 (6)*注記

もっと見る

参考文献 (28)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ